December 14, 2022 08:00 ET | Source: Third Pole Therapeutics Funding will support the final development phase prior to planned 2023 FDA submission of the company’s “breakthrough” designated eNOcare™ hospital device WALTHAM, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) — Third Pole … Continued
July 21, 2022 10:00 AM Eastern Daylight Time CINCINNATI–(BUSINESS WIRE)–BiOWiSH Technologies, Inc. and SABIC Agri-Nutrients Company (SABIC AN) announced the successful completion of a year-long technical evaluation of BiOWiSH® Crop Liquid technology coated on SABIC’s urea in nine countries across five continents … Continued
PITTSBURGH, Pa. & SHORT HILLS, N.J.–(BUSINESS WIRE)–Jul 12, 2022– Areteia Therapeutics, Inc. (“Areteia”) today announces its launch as a clinical-stage biopharmaceutical company focused on putting asthma patients in better control of their disease – and back in control of their … Continued
– Acquisition of next-generation Kv7 channel activators for target indications including epilepsy, pain disorders and affective disorders – BHV-7000 is the lead asset from Kv7 channel platform and is potentially a best-in-class potassium channel activator with a profile suggestive for … Continued
– eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year – Funding will support device optimization and … Continued
NEW YORK, January 24, 2022 (Newswire.com) – Few industries have been as exciting and disruptive in recent years as the burgeoning fintech space. Between the evolution of digital payment methods and checkout options, and increased access to alternative investment opportunities for … Continued
Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases. Asthma affects more than 300 million people worldwide, and is the most common noncommunicable disease among children. No cure exists for chronic asthma; most patients … Continued
Leading alternative investment platform growing at a record pace NEW YORK–(BUSINESS WIRE)–Yieldstreet, a leading multi-asset alternative investment platform, is pleased to announce that Deloitte ranked it once again among the fastest growing technology companies in the U.S. as part of … Continued
Yieldstreet, a leading multi-asset alternative investment platform, has closed a strategic $50 million follow-on investment, led by London-based Mayfair Equity Partners, a leading technology and consumer growth investor. The latest capital raise, following on from Yieldstreet’s Series C funding round, … Continued
LOS ANGELES, Sept. 16, 2021 /PRNewswire/ — Today, Omaze, the leading social impact fundraising platform that offers the chance to win once-in-a-lifetime prizes to support charities around the world, announced that it has secured $85 million in new capital. The round was led by Louis Bacon’s Moore Strategic … Continued
